Related Experiment Video

Updated: May 11, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Targeting the PI3K-AKT-mTOR signaling network in cancer

Khurum H Khan1, Timothy A Yap, Li Yan

  • 1The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

Chinese Journal of Cancer
|May 7, 2013
PubMed

Insights

Targeting the PI3K-AKT-mTOR pathway with new drugs shows promise for cancer treatment. Research focuses on overcoming resistance and improving patient response duration through biomarkers and combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase-AKT-mammalian target of rapamycin (PI3K-AKT-mTOR) pathway is crucial for cancer cell growth and survival.
  • mTOR inhibitors like everolimus and temsirolimus are approved for certain cancers, but patient response duration is often suboptimal.

Purpose of the Study:

  • To review novel targeted therapies for the PI3K-AKT-mTOR pathway currently in clinical development.
  • To discuss the biological rationale, predictive biomarkers, and combination strategies to overcome resistance to these agents.

Main Methods:

  • Literature review of ongoing clinical trials and preclinical studies.
  • Analysis of resistance mechanisms and potential therapeutic interventions.
  • Exploration of biomarker-driven approaches and rational drug combinations.

Main Results:

  • Multiple novel agents targeting key nodes of the PI3K-AKT-mTOR pathway are under active clinical investigation.
  • Understanding resistance mechanisms is critical for developing effective treatment strategies.
  • Predictive biomarkers and combination therapies are essential for improving patient outcomes.

Conclusions:

  • Continued research into novel PI3K-AKT-mTOR pathway inhibitors is vital for advancing cancer therapy.
  • Biomarker discovery and strategic drug combinations hold significant potential to enhance treatment efficacy and overcome resistance.
  • The development of targeted therapies requires a multifaceted approach to address the complexities of this pathway in cancer.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...